Novasep signs deals to build in Japanese market

Novasep has signed two partnership agreements for the Japanese markets.  The agreements were with Allied Laboratories, a life science and chemical consulting company, and with AR Brown, which will represent Novasep’s CMO services in the Japanese market. 

Allied Laboratories now provides business development and technical services for the French CRO’s chromatography and bio-process equipment in the Japanese market, with Novasep Asia, the company’s Shanghai-based processed development and engineering centre.

Allied Laboratories will also support Novasep team enabling them to better serve Japanese customers in a time efficient manner with services such as commissioning, customer services, and training of engineering teams,” Novacep director of marketing Sophie Baudouin explains.

Novasep Asia has been in Shanghai, China, for over 20 years now, where it designs and supplies chromatography purification systems for pharmaceutical and biopharmaceutical companies, as well as supplying locally to the food and feed industries.

The agreement with Allied Laboratories will help reinforce Novasep's proximity to Japanese customers,” Baudouin notes.

The second agreement was signed with AR Brown to represent its CMO services, including both chemical and biological custom manufacturing businesses. 

Novacep already has a solid track record with Japanese customers for contract manufacturing services. We have established relationships with major Japanese pharmaceutical companies.  Our customers will benefit from an efficient communication and local expertise with the AR Brown team,” Baudouin says.

Novacep adds that the agreements will allow them provide high-efficiency purification technologies and custom manufacturing facilities to Japanese customers. It will facilitate the company in supporting challenging projects with a local team in a time-efficient manner.

The Japanese pharmaceutical market is among the top 5 innovative markets. The partnership deals we announced recently will enable Novasep to develop in the area offering both our custom manufacturing services and purification equipment,” Baudouin explains. 

Novacep’s Asian operation has centred in Shanghai, but the CRO opened offices in India and Thailand in 2013 and 2014, respectively. 

Both regions present opportunities for strong growth.  We recently announced the deal for a facility in Vietnam to produce sorbitol,” Baudouin says.

On the pharmaceutical side, we see good opportunities for growth as a result of demand in Chinese and South East markets which are developing active pharmaceutical ingredients production capacities.”

Novasep is a global provider of manufacturing solutions for life sciences molecules and fine chemicals. Its offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

I am delighted to count Allied Laboratories and AR Brown as our business partners in Japan,” said Michel Spagnol, chairman and CEO of Novasep. “These agreements with two renowned and trusted Japanese partners are a key step to reinforcing our local presence, in line with the deployment of our growth strategy.”